摘要
目的:探讨膀胱癌转录因子E2F-1、E2F-3的表达及临床意义。方法:应用免疫组织化学方法检测39例膀胱癌与12例正常膀胱粘膜中E2F-1、E2F-3的表达,以统计学方法分析其表达与肿瘤分级、分期、复发之间的关系。结果:E2F-1在膀胱癌组织与正常膀胱粘膜中的阳性表达率分别为82.1%(32/39)和41.7%(5/12),差异有统计学意义(P<0.05)。癌组织E2F-1的表达在不同的临床病理特征之间差异无显著性;E2F-3在膀胱癌组织与正常膀胱粘膜中的阳性表达率分别为53.8%(21/39)和91.7%(11/12),差异有显著性(P<0.05)。癌组织中E2F-3的表达在不同的分级、分期之间差异有显著性(P<0.05)。结论:E2F的异常表达参与膀胱癌的发病过程,并可在一定程度上反映肿瘤的恶性程度。
Objective:To study the expression and clinical significance of E2F-1 and E2F-3 in bladder carcinoma. Methods: Immunohistochemistry staining was used to detect the expression of E2F-1 and E2F-3 in 39 cases of bladder carcinoma and 12 normal bladder tissues. Statistics was used to analyze the data. Results: The positive expression rate of E2F- 1 in cancer tissues was 82.1 % (32/39), which was significantly higher than 41.7 % (5/12) in normal bladder tissue ( P 〈0. 05). The expression of E2F-1 in carcinoma tissues was not correlated with tumor grade, stage and recurrence ( P 〈0.05). The positive expression rate of E2F-3 in cancer tissues was 53.8% (21/ 39), which was significantly lower than 91.7%(11/12) in normal bladder tissue ( P 〈0.05). The expression of E2F-3 was closely associated with tumor grade and stage (p〈0. 05). Conclusions: Aberrant expression of E2F may play an important role in development and progression of bladder carcinoma, and can be used in predicting tumor malignancy.
出处
《临床泌尿外科杂志》
2007年第1期60-62,共3页
Journal of Clinical Urology